The Effect of Alogliptin on Progression of Atherosclerosis and Renal Function in Type 2 Diabetes Patient with Coronary Artery Disease

The Effect of Alogliptin on Progression of Atherosclerosis and Renal Function in Type 2 Diabetes Patient with Coronary Artery Disease - The Effect of Alogliptin on Atherosclerosis and Renal Function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008077

Enrollment

Registered

2012-06-01

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes patient with coronary artery disease

Interventions

Alogriptin 25mg/day (12.5mg/day for patient with renal dysfunction) for 6 months Voglibose 0.9mg/day for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patient with coronary artery disease

Exclusion criteria

Exclusion criteria: The patients contraindication for Alogriptin, type 1 diabetes patient, the patients already receiving medication for diabetes

Design outcomes

Primary

Measure	Time frame
The progression of coronary artery plaque, endothelial function and renal function at 6 months after intervention	—

Countries

Japan

Contacts

Public ContactYoshiyuki Furuse

Tottori University Faculty of Medicine, Department of Molecular Medicine and Therapeutics

yfuruse-circ@umin.ac.jp0859-38-6517

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026